Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Delayed Quote. Delayed  - 05/25 08:01:16 am
62.846 EUR   -6.76%
05/02 UCB FIRST THREE :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : shareholder meeting today
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Deutsche Boerse Ag
05/19/2016 05/20/2016 05/23/2016 05/24/2016 05/25/2016 Date
65.94(c) 66.223(c) 68.933(c) 67.4(c) 62.846(c) Last
453 0 5 0 0 Volume
-0.35% +0.43% +4.09% -2.22% -6.76% Change
More quotes
Financials (€)
Sales 2016 4 042 M
EBIT 2016 724 M
Net income 2016 453 M
Debt 2016 1 026 M
Yield 2016 1,98%
Sales 2017 4 285 M
EBIT 2017 879 M
Net income 2017 553 M
Debt 2017 676 M
Yield 2017 2,07%
P/E ratio 2016 24,52
P/E ratio 2017 19,83
EV / Sales 2016 3,28x
EV / Sales 2017 3,01x
Capitalization 12 213 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of UCB SA
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB SA
05/19 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
04/21 UCB : Patent Issued for Chiral Intermediate, Process for Producing the Same and ..
More news
Sector news : Pharmaceuticals - NEC
04:36a CHUGAI PHARMACEUTICAL : Bispecific Antibody “ACE910/Emicizumab” Phas..
04:31a CHUGAI PHARMACEUTICAL : Bispecific Antibody "ACE910/Emicizumab" Phase l Data in ..
03:06aDJCSL : says FDA Approves Long-Lasting Haemophilia A Therapy
More sector news : Pharmaceuticals - NEC
Comments 
Advertisement
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions